Trials / Completed
CompletedNCT03798106
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
A Phase II Trial of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may warrant further combination.
Detailed description
Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR-α and -β; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. Pro-angiogenic factors suppress various immune functions whereas antiangiogenic agents have potential to modulate the tumor microenvironment and improve immunotherapy. An analysis of patients with RCC treated with pazopanib demonstrated that elevated expression of PD-L1 correlates with shorter PFS. Investigator also identified 43% of PD-L1 expression in STS and PD-L1 expression had worse overall survival (5-year survival rate: 48% in PD-L1 positive vs. 68% in PD-L1 negative, p=0.015). In detail, PD-L1 expression was reported 52.6% in synovial sarcoma, 37.6% in rhabdomyosarcoma, and 100% in epithelioid sarcoma. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may warrant further combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Durvalumab, pazopanib | Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks |
Timeline
- Start date
- 2019-04-10
- Primary completion
- 2022-08-10
- Completion
- 2022-08-10
- First posted
- 2019-01-09
- Last updated
- 2023-06-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03798106. Inclusion in this directory is not an endorsement.